MAIA Biotechnology
View On Demand

Early Data Shows THIO Has The Potential To Stop Cancer In Its Tracks

About the Event

MAIA Biotechnology received preliminary data from its Phase 2 Clinical trial for non-small cell lung cancer and the results are very promising. The first 2 patients dosed with THIO continue to be without documented disease progression for 12.2 and 11.5 months, while most patients only live for 3-4 months. In addition, the study shows a preliminary disease control rate (DCR) of 82%, compared to typical DCRs which are in the 25-35% range for chemotherapy.

Watch this fireside chat with MAIA CEO, Dr. Vlad Vitoc, to hear more about these results and the company’s other programs which expand the company’s options to treat several cancer indications.

View On Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.